Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00050661

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody/ Placebo to Prevent Relapse of Psoriasis Vulgaris Following NBUVB Therapy

Sponsor: Facet Biotech

Conditions Psoriasis

Interventions Daclizumab NB-UVB

Updated 6 times since 2017 Last updated: Mar 24, 2009 Started: Oct 31, 1997 Primary completion: Apr 30, 2004 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Psoriasis and is currently completed. Facet Biotech leads this study, which shows 6 recorded versions since 1997 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Facet Biotech
Rockefeller University

Data source: Rockefeller University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States